117 related articles for article (PubMed ID: 9213912)
1. [Does alendronate reduce the risk of fractures in postmenopausal women with osteoporosis?].
Häuselmann HJ
Praxis (Bern 1994); 1997 Apr; 86(15):613. PubMed ID: 9213912
[No Abstract] [Full Text] [Related]
2. Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Can Fam Physician; 2003 Apr; 49():487. PubMed ID: 12729244
[No Abstract] [Full Text] [Related]
3. [Fast protection against osteoporotic fractures by using alendronat].
Orthopade; 1999 Apr; 28(4 Suppl):1-4. PubMed ID: 10337656
[No Abstract] [Full Text] [Related]
4. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
Jönsson L; Borgström F; Zethraeus N
Ugeskr Laeger; 2003 Oct; 165(43):4112-6. PubMed ID: 14619061
[No Abstract] [Full Text] [Related]
5. [Alendronate also for women without established osteoporosis?].
Klovning A; Norheim OF
Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1347-51. PubMed ID: 10868100
[No Abstract] [Full Text] [Related]
6. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
[TBL] [Abstract][Full Text] [Related]
7. [Alendronate (Fosamax 10 mg). The first amino-biphosphate for the treatment of women with postmenopausal osteoporosis].
Geburtshilfe Frauenheilkd; 1996 Oct; 56(10 Suppl):1-4. PubMed ID: 9022376
[No Abstract] [Full Text] [Related]
8. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
9. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis screening: time to take responsibility.
Mazanec D
Arch Intern Med; 2004 May; 164(10):1047-8. PubMed ID: 15159261
[No Abstract] [Full Text] [Related]
11. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
12. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
[No Abstract] [Full Text] [Related]
13. [Working title: Will reducing alendronate increase the risk of bone fractures by a decrease in bone density? Benefit from alendronate therapy for women without prior fractures remains uncertain].
Ritzmann P
Praxis (Bern 1994); 1999 Sep; 88(40):1631-2. PubMed ID: 10536501
[No Abstract] [Full Text] [Related]
14. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
15. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
16. [Alendronate once a week].
Brixen KT; Mosekilde L
Ugeskr Laeger; 2003 Jun; 165(27):2734-9. PubMed ID: 12886563
[No Abstract] [Full Text] [Related]
17. [Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review].
Eiken PA; Abrahamsen B
Ugeskr Laeger; 2009 Mar; 171(11):903-6. PubMed ID: 19278615
[No Abstract] [Full Text] [Related]
18. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
20. [New knowledge on alendronate (Fosamax) and fractures].
Kopjar B; Bjørndal A
Tidsskr Nor Laegeforen; 1999 Feb; 119(5):702. PubMed ID: 10095398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
